Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | G6PD | P11413 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.34 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2282004 | 0.87 | GAA (0.35) | CA12CA1CA2CA4CA7 | |
| SCHEMBL2284733 | 0.85 | PDE3B (0.32) | KDM4EMAPTS1PR4HSP90AA1G6PD | |
| SCHEMBL2286343 | 0.84 | TAAR1 (0.32) | HTR2AHTR2CHTR2B | |
| SCHEMBL2286239 | 0.84 | POLB (0.34) | MAPTNPSR1 | |
| SCHEMBL2291144 | 0.79 | HTR2A (0.34) | MAPTGAAHTR2AHTR2C | |
| SCHEMBL27743262 | 0.79 | TAAR1 (0.37) | GAANPC1HTR2AHTR2CHTR2B | |
| SCHEMBL943527 | 0.75 | ALDH1A1 (0.37) | CA9KDM4EMAPTS1PR4HSP90AA1 | |
| SCHEMBL2289162 | 0.75 | GAA (0.34) | KDM4EMAPTS1PR4HSP90AA1G6PD | |
| SCHEMBL76231 | 0.74 | ACHE (0.48) | CA12CA1CA2CA4CA7 | |
| SCHEMBL312352 | 0.74 | CA12 (0.36) | CA12CA1CA2CA4CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110354128-A | Pyrimidine FGFR4 inhibitors | 卫材R&D管理有限公司 | 2019-10-22 | — | — | CN | claimed |
| CN-109803684-A | Combination therapy for the treatment of hepatocellular carcinoma | 卫材 R&D 管理有限公司 | 2019-05-24 | — | — | CN | claimed |
| EP-2544679-B1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORP (US) | 2019-05-15 | — | — | EP | claimed |
| CN-109718239-A | For treating the FGFR inhibitor of low-phosphorous hemorrhagic disease | 诺华股份有限公司 | 2019-05-07 | — | — | CN | claimed |
| CN-109476672-A | NOVEL HETEROCYCLIC DERIVATIVE COMPOUND AND USE THEREOF | 韩美药品株式会社 | 2019-03-15 | — | — | CN | claimed |
| CN-104710385-B | PDE10 inhibitor and compositions related and method | 奥默罗斯公司 | 2018-11-09 | — | — | CN | claimed |
| US-10106516-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2018-10-23 | — | — | US | claimed |
| CN-108348519-A | Chlorobenzene-substituted azaaryl compounds | 台北医学大学 | 2018-07-31 | — | — | CN | claimed |
| CN-106459034-B | Carbostyril derivative as fibroblast growth factor acceptor inhibitor | 普林斯匹亚生物制药公司 | 2018-01-12 | — | — | CN | claimed |
| US-20170152238-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION | 2017-06-01 | — | — | US | claimed |
| CN-106459034-A | Quinolone derivatives as fibroblast growth factor receptor inhibitors | 普林斯匹亚生物制药公司 | 2017-02-22 | — | — | CN | claimed |
| US-20130196994-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2013-08-01 | — | — | US | claimed |
| EP-2544679-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | Omeros Corporation (US) | 2013-01-16 | — | — | EP | claimed |
| US-8343970-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2013-01-01 | — | — | US | claimed |
| CN-102741256-A | Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase | HANMI PHARM IND CO LTD | 2012-10-17 | — | — | CN | claimed |
| WO-2011112828-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2011-09-15 | — | — | WO | claimed |
| US-20110224202-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2011-09-15 | — | — | US | claimed |
| EP-0888303-B1 | SYNTHETIC DERIVATIVES OF RAPAMYCIN AS MULTIMERIZING AGENTS FOR CHIMERIC PROTEINS WITH IMMUNOPHILIN-DERIVED DOMAINS | ARIAD PHARMA INC (US) | 2010-04-21 | — | — | EP | claimed |
| EP-0888303-A1 | SYNTHETIC DERIVATIVES OF RAPAMYCIN AS MULTIMERIZING AGENTS FOR CHIMERIC PROTEINS WITH IMMUNOPHILIN-DERIVED DOMAINS | ARIAD GENE THERAPEUTICS, INC. (US) | 1999-01-07 | — | — | EP | claimed |
| WO-1997031898-A1 | SYNTHETIC DERIVATIVES OF RAPAMYCIN AS MULTIMERIZING AGENTS FOR CHIMERIC PROTEINS WITH IMMUNOPHILIN-DERIVED DOMAINS | ARIAD GENE THERAPEUTICS, INC. (US) | 1997-09-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10106516-B2 | PDE10 inhibitors and related compositions and methods | PDE10A, PDE9A, PDE7A | CA12 1180/4885CA1 160/4885CA2 788/4885 |
| US-20130196994-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | PDE10A, PDE9A, PDE7A | CA12 1180/4885CA1 160/4885CA2 788/4885 |
| US-20170152238-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | PDE10A, PDE9A, PDE7A | CA12 1180/4885CA1 160/4885CA2 788/4885 |
| US-20110224202-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | PDE10A, PDE9A, PDE7A | CA12 1180/4885CA1 160/4885CA2 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.